MDBriefCase will be unavailable due to maintenance from Sunday, January 14 11PM to Monday, January 15 1AM ET.


Breast Cancer Awareness Month: New Developments and Treatment Advances

Breast cancer is the second most common type of cancer in Canadian women, surpassed only by non-melanoma skin cancer.

Breast cancer accounts for approximately 25 percent of new cases of cancer and 13 percent of all cancer deaths in Canadian women. It is expected that one in every eight women in Canada will develop breast cancer in her lifetime, and one in 33 will die of it.  On average, 78 Canadian women are diagnosed with breast cancer each day, and 15 die from it. Ductal carcinoma is the most common type of breast cancer, accounting for about 90 percent of all in situ breast carcinomas and 70 percent of all invasive breast carcinomas. 

The Challenge

Part of the challenge breast cancer presents is that there are so many different types, and they are treated differently. Some breast cancer cells have characteristics that make them easier to treat. For example, newly diagnosed breast cancer cells are tested for the presence of hormone receptors, the proteins that fuel cancer growth. Breast cancers with cells that have hormone receptors are classified as hormone-receptor-positive (HR+).

Approximately two-thirds of breast cancers have at least one type of hormone receptor. Breast tumours may be positive for estrogen receptors (ER+), for progesterone receptors (PR+), or for both estrogen and progesterone receptors(ER/PR+). About 80 percent of all HR+ breast cancers are ER+ or ER/PR+/.

Two other types of breast cancer are HER2-positive and HER2-negative. HER2 stands for human epidermal growth factor receptor 2, a protein that normally helps control the growth and repair of healthy breast tissue. Sometimes, though, the HER2 gene becomes faulty and makes too many copies of itself, overproducing HER2 proteins on the surface of breast cells. This can result in HER2-positive breast cancer.

In about 20 percent of breast cancers, the cancer cells have extra copies of the gene that makes HER2 protein. HER2-positive breast cancers tend to be more aggressive than other types of breast cancer; however, treatments that target HER2 specifically are very effective.

HER2-negative breast cancer is generally divided into two types, HR+ breast cancer and triple-negative breast cancer, based on the presence or absence of hormone receptors on the surface of the cancer cells.

HER2-Low Breast Cancer 

About half of patients with metastatic breast cancer have tumours with low levels of the HER2 protein. Until now, these patients have had limited treatment options. But the results of recent clinical trials could open the door to more effective treatment for these patients.

Treatment with an antibody conjugate (a combination of a monoclonal antibody with a chemotherapy agent) that is delivered via infusion into a vein shows promising results. The monoclonal antibody acts as a homing device that helps deliver the chemotherapy drug directly to the tumour, where it is released and kills the cells.

Patients in one recent trial employing this technique who were treated with trastuzumab deruxtecan (Enhertu®) lived nearly twice as long without their cancer growing and lived six months longer overall as those who received standard chemotherapy. The trial findings are expected to change how metastatic HER2-low breast cancer is treated.

As research expands beyond traditional research and adds incremental steps to standard therapy, physicians will be able to help more breast cancer patients. That provides a ray of hope for the nearly 28,600 women who are predicted to be diagnosed with breast cancer this year, and all who will follow in the coming years. 

Keep Your Knowledge Current

Explore the most timely and clinically-relevant educational resources focused in the area of breast cancer at OncologyEducation.

OncologyEducation and MDBriefCase are members of the Think Research family of companies.

Author Agreement

In submitting your work (the “Work”) for potential posting on the MDBriefCase Healthcare Leadership Academy website (the “Website”), you (“You”) expressly agree to the following:

Review: MDBriefCase is pleased to consider the publication of Your Work on the Website.   The suitability of the Work for posting shall be determined by MDBRiefCase at its sole discretion. Nothing herein shall obligate MDBriefcase to post or otherwise publish the Work, or the maintain its posting in future.   

Editing; Identification: MDBriefcase shall have the right to edit the Work to conform to our standards of style, technological requirements, language usage, grammar and punctuation, provided that the meaning of the Work is not materially altered.  If posted, You will be identified as the author of the Work, or co-author if applicable.  

Grant of Rights:  As a condition of publication and for no monetary compensation, You hereby grant to MDBriefCase the following rights to the Work in any and all media whether now existing or hereafter developed, including print and electronic/digital formats:  (1) the exclusive right of first publication worldwide;  (2) the perpetual non-exclusive worldwide right to publish, reproduce, distribute, sell, adapt, perform, display, sublicense, and create derivative works, alone or in conjunction with other materials; (3) the perpetual non-exclusive worldwide right to use the Work, or any part thereof, in any other publication produced by MDBriefCase and/or on MDBriefCase’s website; and (4) the perpetual non-exclusive worldwide right to use the Work to promote and publicize MDBriefCase or its publications.  The grant of rights survives termination or expiration of this Agreement.    

Warranty:  You warrant that the Work is original with You and that it is not subject to any third party copyright; that You have authority to grant the rights in this Agreement; that publication of the Work will not libel anyone or infringe on or invade the rights of others; that You have full power and authority to enter into this Agreement; that the Work has not been published elsewhere in whole or in part; and that You have obtained permission from the copyright owner consistent with this Agreement for any third party copyrighted material in the Work.  This warranty survives termination or expiration of this Agreement.

Submission Agreement

Thank you for your interest in writing an article for the MDBriefCase Healthcare Leadership Academy website.

Audience and Appropriate Topics

The  Healthcare Leadership Academy welcomes submissions on all topics relevant to leaders in healthcare. Our topics include Leading in Healthcare, Leadership Lessons from COVID-19 and others. We prioritize stories that provide leadership advice to executives and managers in healthcare companies, offer actionable strategies for executing successful projects, and provide interesting angles on current healthcare topics. Submissions must be original work of the authors and unpublished.  When submitting, authors represent that they have included no material that is in violation of the rights of any other person or entity.


Articles must be educational and non-promotional. If they mention the author’s company or any of the company’s products or services by name within the text, such mention should be very limited and used for reference only, not for promotion. (For example, an author might cite a survey conducted by his company but not describe his company’s product as a solution to a business problem.) Articles will be edited for clarity, style and brevity. The final headline is determined by the editor.

Length of Submissions

Guest articles for the MDBriefCase Healthcare Leadership Academy may run between 500 and 1000 words. 


MDBriefCase reserves the right to accept or reject any submission  and the right to condition acceptance upon revision of material to conform to its criteria.   

No Compensation

There is no payment for contributed articles. However, MDBriefCase will give the author a byline. Authors are invited to link to the article on personal  websites, corporate websites and social media platforms.

Author Agreements

Each author understands and agrees that any submission accepted for posting is provided subject to MDBriefCase’s Author Agreement